Advertisement

Indian Journal of Surgical Oncology

, Volume 2, Issue 2, pp 88–100 | Cite as

Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review

  • Umashankar K. Ballehaninna
  • Ronald S. ChamberlainEmail author
Review Article

Abstract

Pancreatic cancer is an aggressive tumor with a dismal prognosis, biomarkers that can detect tumor in its early stages when it may be amenable to curative resection may improve prognosis. At present, serum CA 19-9 is the only validated tumor marker in widespread clinical use, but precise knowledge of its role in pancreatic cancer diagnosis, staging, determining resectability, response to chemotherapy and prognosis remains limited. A comprehensive search was performed using PubMed with keywords “pancreatic cancer” “tumor markers” “CA 19-9” “diagnosis” “screening” “prognosis” “resectability” and “recurrence”. All English language articles pertaining to the role of CA 19-9 in pancreatic cancer were critically analyzed to determine its utility as a biomarker for pancreatic cancer. Serum CA 19-9 is the most extensively studied and clinically useful biomarker for pancreatic cancer. Unfortunately, CA 19-9 serum level evaluation in pancreatic cancer patients is limited by poor sensitivity, false negative results in Lewis negative phenotype (5–10%) and increased false positivity in the presence of obstructive jaundice (10–60%). Serum CA 19-9 level has no role in screening asymptomatic populations, and has a sensitivity and specificity of 79–81% and 82–90% respectively for the diagnosis of pancreatic cancer in symptomatic patients. Pre-operative CA 19-9 serum level provide useful prognostic information as patients with normal CA 19-9 serum levels (<37 U/ml) have a prolonged median survival (32–36 months) compared to patients with elevated CA 19-9 serum levels (>37 U/ml) (12–15 months). A CA 19-9 serum level of <100 U/ml implies likely resectable disease whereas levels >100 U/ml may suggest unresectablity or metastatic disease. Normalization or a decrease in post-operative CA 19-9 serum levels by ≥20–50% from baseline following surgical resection or chemotherapy is associated with prolonged survival compared to failure of CA 19-9 serum levels to normalize or an increase. Carbohydrate antigen (CA 19-9) is the most extensively studied and validated serum biomarker for the diagnosis of pancreatic cancer in symptomatic patients. The CA 19-9 serum level can provide important information with regards to prognosis, overall survival, and response to chemotherapy as well as predict post-operative recurrence. Non-specific expression in several benign and malignant diseases, false negative results in Lewis negative genotype and an increased false positive results in the presence of obstructive jaundice severely limit the universal applicability of serum CA 19-9 levels in pancreatic cancer management.

Keywords

Pancreatic cancer Tumor markers CA 19-9 Diagnosis Screening Prognosis Resectability Recurrence 

References

  1. 1.
    GLOBOCAN (2008) (International Agency for Research in Cancer) Section of Cancer Information. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. Accessed 12 December 2010.
  2. 2.
    Ellison LF, Wilkins K (2010) An update on cancer survival. Health Rep 21(3):55–60PubMedGoogle Scholar
  3. 3.
    Yeole BB, Kumar AV (2004) Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India. Asian Pac J Cancer Prev 5(2):175–182PubMedGoogle Scholar
  4. 4.
    Gillen S, Schuster T, Meyer zum Büschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267PubMedCrossRefGoogle Scholar
  5. 5.
    Harsha HC, Kandasamy K, Ranganathan P et al (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6(4):e1000046PubMedCrossRefGoogle Scholar
  6. 6.
    Koprowski H, Steplewski Z, Mitchell K et al (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5:957–972PubMedCrossRefGoogle Scholar
  7. 7.
    Kannagi R (2007) Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 30(3):189–209PubMedGoogle Scholar
  8. 8.
    Safi F, Roscher R, Bittner R et al (1987) High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 2:398–403PubMedCrossRefGoogle Scholar
  9. 9.
    Duraker N, Hot S, Polat Y et al (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95(2):142–147PubMedCrossRefGoogle Scholar
  10. 10.
    Liao Q, Zhao YP, Yang YC et al (2007) Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 6(6):641–645PubMedGoogle Scholar
  11. 11.
    Vestergaard EM, Hein HO, Meyer H et al (1999) Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 45(1):54–61PubMedGoogle Scholar
  12. 12.
    Ritts RE, Pitt HA (1998) CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 7(1):93–101PubMedGoogle Scholar
  13. 13.
    Kim HJ, Kim MH, Myung SJ et al (1999) A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 94(7):1941–1946PubMedCrossRefGoogle Scholar
  14. 14.
    Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3):266–270PubMedCrossRefGoogle Scholar
  15. 15.
    Duffy MJ, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21(3):441–447PubMedCrossRefGoogle Scholar
  16. 16.
    Kim JE, Lee KT, Lee JK et al (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19(2):182–186PubMedCrossRefGoogle Scholar
  17. 17.
    Satake K, Takeuchi T, Homma T et al (1994) CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 9(6):703–706PubMedCrossRefGoogle Scholar
  18. 18.
    Chang CY, Huang SP, Chiu HM et al (2006) Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 53(67):1–4PubMedGoogle Scholar
  19. 19.
    Tessler DA, Catanzaro A, Velanovich V et al (2006) Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 91(2):191–197CrossRefGoogle Scholar
  20. 20.
    Steinberg W (1990) The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85(4):350–355PubMedGoogle Scholar
  21. 21.
    Pleskow DK, Berger HJ, Gyves J et al (1989) Evaluation of a serologic marker, CA19-9 in the diagnosis of pancreatic cancer. Ann Intern Med 110(9):704–709PubMedGoogle Scholar
  22. 22.
    Safi F, Schlosser W, Kolb G et al (1997) Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 2:106–112CrossRefGoogle Scholar
  23. 23.
    Jiang XT, Tao HQ, Zou SC et al (2004) Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3(3):464–468PubMedGoogle Scholar
  24. 24.
    Ferrone CR, Finkelstein DM, Thayer SP et al (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24(18):2897–2902PubMedCrossRefGoogle Scholar
  25. 25.
    Kim YC, Kim HJ, Park JH et al (2009) Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 24(12):1869–1875PubMedCrossRefGoogle Scholar
  26. 26.
    Kondo N, Murakami Y, Uemura K et al (2010) Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 17(9):2321–2329PubMedCrossRefGoogle Scholar
  27. 27.
    DeWitt J, Devereaux B, Chriswell M et al (2004) Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 141(10):753–763PubMedGoogle Scholar
  28. 28.
    Ritts RE Jr, Nagorney DM et al (1994) Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 9(6):707–716PubMedCrossRefGoogle Scholar
  29. 29.
    Paganuzzi M, Onetto M, Marroni P et al (1988) CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 61(10):2100–2108PubMedCrossRefGoogle Scholar
  30. 30.
    Nakao A, Oshima K, Nomoto S et al (1998) Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol 15(1):15–22PubMedCrossRefGoogle Scholar
  31. 31.
    Kau SY, Shyr YM, Su CH (1999) Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg 188(4):415–420PubMedCrossRefGoogle Scholar
  32. 32.
    Schlieman MG, Ho HS, Bold RJ et al (2003) Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138:951–955PubMedCrossRefGoogle Scholar
  33. 33.
    Kiliç M, Göçmen E, Tez M et al (2006) Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 49(4):241–244PubMedGoogle Scholar
  34. 34.
    Fujioka S, Misawa T, Okamoto T (2007) Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 14(6):539–544PubMedCrossRefGoogle Scholar
  35. 35.
    Maithel SK, Maloney S, Winston C et al (2008) Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15(12):3512–3520PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang S, Wang YM, Sun CD et al (2008) Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 14(23):3750–3753PubMedCrossRefGoogle Scholar
  37. 37.
    Halloran CM, Ghaneh P, Connor S et al (2008) Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 95(4):453–459PubMedCrossRefGoogle Scholar
  38. 38.
    Sperti C, Pasquali C, Catalini S et al (1993) CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 52(3):137–141PubMedCrossRefGoogle Scholar
  39. 39.
    Lundin J, Roberts PJ, Kuusela P et al (1994) The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 69(3):515–519PubMedCrossRefGoogle Scholar
  40. 40.
    Ikeda M, Okada S, Tokuuye K et al (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91(3):490–495PubMedCrossRefGoogle Scholar
  41. 41.
    Saad ED, Machado MC, Wajsbrot D et al (2002) Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 32(1):35–41PubMedCrossRefGoogle Scholar
  42. 42.
    Micke O, Bruns F, Schäfer U et al (2003) CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 23(2A):835–840PubMedGoogle Scholar
  43. 43.
    Berger AC, Meszoely IM, Ross EA et al (2004) Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11(7):644–649PubMedCrossRefGoogle Scholar
  44. 44.
    Maisey NR, Norman AR, Hill A et al (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93(7):740–743PubMedCrossRefGoogle Scholar
  45. 45.
    Smith RA, Bosonnet L, Ghaneh P et al (2008) Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 25(3):226–232PubMedCrossRefGoogle Scholar
  46. 46.
    Waraya M, Yamashita K, Katagiri H et al (2009) Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 16(5):1231–1240PubMedCrossRefGoogle Scholar
  47. 47.
    Turrini O, Schmidt CM, Moreno J et al (2009) Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg 13(10):1791–1797PubMedCrossRefGoogle Scholar
  48. 48.
    Wasan HS, Springett GM, Chodkiewicz C et al (2009) CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer 101(7):1162–1167PubMedCrossRefGoogle Scholar
  49. 49.
    Katz MH, Varadhachary GR, Fleming JB et al (2010) Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17(7):1794–1801PubMedCrossRefGoogle Scholar
  50. 50.
    Montgomery RC, Hoffman JP, Riley LB et al (1997) Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4(7):551–556PubMedCrossRefGoogle Scholar
  51. 51.
    Hernandez JM, Cowgill SM, Al-Saadi S (2009) CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 13(2):349–353PubMedCrossRefGoogle Scholar
  52. 52.
    Nishida K, Kaneko T, Yoneda M et al (1999) Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 71(3):140–146PubMedCrossRefGoogle Scholar
  53. 53.
    Ishii H, Okada S, Sato T et al (1997) CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 44(13):279–283PubMedGoogle Scholar
  54. 54.
    Gogas H, Lofts FJ, Evans TR et al (1998) Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 77(2):325–328PubMedCrossRefGoogle Scholar
  55. 55.
    Halm U, Schumann T, Schiefke I et al (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82(5):1013–1016PubMedCrossRefGoogle Scholar
  56. 56.
    Stemmler J, Stieber P, Szymala AM et al (2003) Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 26(5):462–467PubMedCrossRefGoogle Scholar
  57. 57.
    Ziske C, Schlie C, Gorschlüter M et al (2003) Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89(8):1413–1417PubMedCrossRefGoogle Scholar
  58. 58.
    Ko AH, Hwang J, Venook AP et al (2005) Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93(2):195–199PubMedCrossRefGoogle Scholar
  59. 59.
    Pohlank K, Hilbig A, Pelzer UJ et al (2008) Decrease of CA 19-9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time. J Clin Oncol 26(15S):15574Google Scholar
  60. 60.
    Reni M, Cereda S, Balzano G et al (2009) Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115(12):2630–2639PubMedCrossRefGoogle Scholar
  61. 61.
    Hess V, Glimelius B, Grawe P et al (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 9(2):132–138PubMedCrossRefGoogle Scholar
  62. 62.
    Fogelman RD, Pathak P, Qiao W et al (2008) Serum CA 19–9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC). J Clin Oncol 26(15S):15514Google Scholar
  63. 63.
    Haas M, Laubender RP, Stieber P et al (2010) Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 31(4):351–357PubMedCrossRefGoogle Scholar
  64. 64.
    Takahashi H, Ohigashi H, Ishikawa O et al (2010) Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 251(3):461–469PubMedCrossRefGoogle Scholar
  65. 65.
    Willett CG, Daly WJ, Warshaw AL et al (1996) CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172(4):350–352PubMedCrossRefGoogle Scholar
  66. 66.
    Boeck S, Haas M, Laubender RP et al (2010) Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 16(3):986–994PubMedCrossRefGoogle Scholar
  67. 67.
    Kang CM, Kim JY, Choi GH et al (2007) The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140(1):31–35PubMedCrossRefGoogle Scholar
  68. 68.
    Decker GA, Batheja MJ, Collins JM et al (2010) Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (NY) 6(4):246–254Google Scholar
  69. 69.
    Bedi MM, Gandhi MD, Jacob G et al (2009) CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 28(1):24–27PubMedCrossRefGoogle Scholar
  70. 70.
    Ulla Rocha JL, Alvarez Sanchez MV, Paz Esquete J et al (2007) Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation. JOP 10;8(2):191–197Google Scholar
  71. 71.
    Paganuzzi M, Onetto M, Marroni P et al (1988) CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 61(10):2100–2108PubMedCrossRefGoogle Scholar
  72. 72.
    Marcouizos G, Ignatiadou E, Papanikolaou GE et al (2009) Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J 30(2):6662CrossRefGoogle Scholar
  73. 73.
    Kim HR, Lee CH, Kim YW et al (2009) Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med 47(6):750–754PubMedCrossRefGoogle Scholar
  74. 74.
    Ventrucci M, Pozzato P, Cipolla A et al (2009) Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 41(5):357–363PubMedCrossRefGoogle Scholar
  75. 75.
    Mery CM, Duarte-Rojo A, Paz-Pineda F et al (2001) Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer? Rev Invest Clin 53(6):511–517PubMedGoogle Scholar
  76. 76.
    Ong SL, Sachdeva A, Garcea G et al (2008) Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 53(12):3213–3217PubMedCrossRefGoogle Scholar
  77. 77.
    Basso D, Meggiato T, Fabris C et al (1992) Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. Clin Investig 70(1):49–54PubMedCrossRefGoogle Scholar
  78. 78.
    Marrelli D, Caruso S, Pedrazzani C et al (2009) CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 198(3):333–339PubMedCrossRefGoogle Scholar
  79. 79.
    Ortiz-González J, Alvarez-Aguila NP, Medina-Castro JM et al (2005) Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma. Anticancer Res 25(5):3625–3627PubMedGoogle Scholar
  80. 80.
    Koopmann J, Rosenzweig CN, Zhang Z et al (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12(2):442–446PubMedCrossRefGoogle Scholar
  81. 81.
    Eguchi H, Ishikawa O, Ohigashi H et al (2009) Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas 38(7):791–798PubMedCrossRefGoogle Scholar
  82. 82.
    Grote T, Logsdon CD (2007) Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 23(5):508–514PubMedCrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2011

Authors and Affiliations

  • Umashankar K. Ballehaninna
    • 1
    • 2
  • Ronald S. Chamberlain
    • 1
    • 3
    • 4
    Email author
  1. 1.Department of Surgery, Saint Barnabas Medical CenterUniversity of Medicine and Dentistry of New Jersey (UMDNJ)LivingstonUSA
  2. 2.Department of SurgeryMaimonides Medical CenterBrooklynUSA
  3. 3.Department of SurgeryUniversity of Medicine and Dentistry of New JerseyNewarkUSA
  4. 4.Saint George’s University School of MedicineGrenadaWest Indies

Personalised recommendations